MedPath

Investigating the Effect of At Home Thermal Therapy on Dry Eye Patients With Meibomian Gland Dysfunction

Not Applicable
Conditions
Dry Eye Disease
Meibomian Gland Dysfunction
Interventions
Device: Thermal therapy device
Registration Number
NCT03291704
Lead Sponsor
UMay Care Inc.
Brief Summary

The purpose of this pilot study is to determine the feasibility of at home thermal therapy with a wireless, portable device, as an effective management of Meibomian Gland Dysfunction.

This will be done by assessing patients for improvement in symptoms and ocular oil gland function after 4 weeks of a daily thermal therapy application.

Detailed Description

This study will be a non-randomized, open label study of subjects with documented MGD. All subjects will be sent home with a wireless, portable thermal therapy device and examined pre and post treatment period. Subjects will be asked to use the device at bedtime for 5 minutes daily for 4 weeks. After treatment subjects will be re-examined and measured for clinical and symptomatic change in their MGD as well as changes to their sleep quality and anxiety index. Subjects will also be followed after treatment has been completed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Clinical diagnosis of MGD
  • Minimum age 18 years
Exclusion Criteria
  • History of ocular disease, trauma, surgery (other than refractive), orbital cancer
  • 3 month history of ocular infection and/or ocular inflammation not associated with dry eye
  • 3 month history of any active physician administered or prescription dry eye treatment
  • Pregnant, potentially pregnant or nursing

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Thermal TherapyThermal therapy deviceHeat application using at home thermal therapy device
Primary Outcome Measures
NameTimeMethod
Change in Non-Invasive Tear Film Break Up Time (NITFBUT) in SecondsBefore and after 4 weeks of daily treatment

Ocular surface analysis of tear film evaporation

Secondary Outcome Measures
NameTimeMethod
Change in Ocular Surface Disease Index (OSDI) ScoreBefore and after 4 weeks of daily treatment

Standardized symptom questionnaire

Meibum ExpressibilityBefore and after 4 weeks of daily treatment

Grade of Meibum oil expressibility from Meibomian Gland

Sleep QualityBefore and after 4 weeks of daily treatment

Pittsburg Sleep Quality Index (PSQI)

State Trait and AnxietyBefore and after 4 weeks of daily treatment

State-Trait Anxiety Index (STAI)

© Copyright 2025. All Rights Reserved by MedPath